Cervical Carcinogenesis and Immune Response Gene Polymorphisms: A Review

Table 2

Overview of polymorphisms in genes encoding anti-inflammatory cytokines and association with cervical neoplasia risk.

Gene		Cohort	Cases	Population	Distribution	Risk (OR, 95% CI);	Reference
IL1RN	VNTR alleles 1–5	Cervical cancer	150	North Indian	Alleles	2: 2.33 (1.57–3.44); 19.4%; 3: 0.89 (0.27–2.77); 4: 1.00 (0.18–5.33)	[13]
					Haplotypes (ILRN-VNTR/IL1B c.-511C>T)	1/T: 1.71 (1.12–2.62); 18.7%; 2/C: 1.98 (0.95–4.14); 2/T: 4.08 (2.38–7.04); 20.1%; 3/T: 1.26 (0.37–4.14); 4/T: 1.89 (0.29–2.23)
IL10	c.-1082A>G (rs1800896)	CIN; Cervical cancer	163; 104	Japanese	Genotypes	CIN; AG/GG: 2.2 (1.2–4.2); 53.9% Cervical cancer; AG/GG: 3.9 (2.1–7.3); 70.8%	[23]
		Cervical cancer	77	African	Genotypes	AG: 0.28 (0.12–0.61)	[24]
		Cervical cancer	667	Caucasian	Alleles	G: 0.39 (0.32–0.47)	[25]
		Cervical cancer	256	Indian	Genotypes	AG/GG: 3.67 (2.33–5.77); 52.2%	[26]
IL10	c.-592C>A (rs1800872)	Cervical cancer	2396	Asian; Caucasian	Alleles	A: 1.16 (1.04–1.31)	[25]
		Cervical cancer	2183	Varied	Alleles	A: 1.17 (1.04–1.33)	[16]
		Squamous intraepithelial cervical lesions	204	Mexican	Alleles	A: 1.32 (0.97–1.81)	[27]
					Genotypes	CA/AA: 2.02(1.26–3.25); 38.4%
		CIN II/III; Cervical cancer	263; 667	Dutch	Genotypes	CIN; CA: 1.44 (1.06–1.97); 11.2%; AA: 1.09 (0.53–2.26); CA/AA: 1.40 (1.04–1.88); 11.7%; Cervical cancer; CA: 1.36 (1.07–1.73); 9.3%; AA: 1.30 (0.73–2.29); CA/AA: 1.34 (1.05–1.72); 10.1%	[28]

n: number of cases; OR: odds ratio; 95% CI: 95% confidence interval; CIN: cervical intraepithelial neoplasia; PAF: population attributable fraction.
variation and dbSNP reference number.
relative to major allele or major allele homozygotes.
listed if OR > 1.00.
associations listed in bold.